New and emerging therapies for the treatment of irritable bowel syndrome: An update for gastroenterologists

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 3, 2016, Pages 354-375

  Foxx Orenstein, Amy E ^a  

^a MAYO CLINIC   (United States)

Author keywords

asimadoline; functional bowel disorder; linaclotide; rifaximin

Indexed keywords

ASIMADOLINE; DELTA OPIATE RECEPTOR; IBODUTANT; KAPPA OPIATE RECEPTOR; LINACLOTIDE; MU OPIATE RECEPTOR; RIFAXIMIN;

ANXIETY; COMORBIDITY; DEPRESSION; DISEASE SURVEILLANCE; DRUG EFFECT; GASTROENTEROLOGIST; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING; WELLBEING;

EID: 84963744541     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16633050     Document Type: Review

References (166)

1. Afari N., Ahumada S., Wright L., Mostoufi S., Golnari G., Reis V., et al. (2014) Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med 76: 2-11.
2. Ahn J., Lee K., Choi C., Kim J., Lee H., Kim J., et al. (2014) Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci 59: 1001-1011.
3. American College of Gastroenterology Task Force on IBS (2009) An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 104: S1-S35.
4. Bagnol D., Mansour A., Akil H., Watson S.J., (1997) Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 81: 579-591.
5. Bajaj J., Heuman D., Sanyal A., Hylemon P., Sterling R., Stravitz R., et al. (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8: e60042.
6. Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., et al. (2011) The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 17: 349-359.
7. Barbara G., Stanghellini V., De Giorgio R., Corinaldesi R., (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 18: 6-17.
8. Bardhan K., Bodemar G., Geldof H., Schütz E., Heath A., Mills J., et al. (2000) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 14: 23-34.
9. Bashashati M., Rezaei N., Shafieyoun A., McKernan D., Chang L., Ohman L., et al. (2014) Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 26: 1036-1048.
10. Bennett A., Whitney B., (1966) A pharmacological study of the motility of the human gastrointestinal tract. Gut 7: 307-316.
11. Böhn L., Störsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., et al. (2015) Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149: 1399-1407.
12. Bradford K., Shih W., Videlock E., Presson A., Naliboff B., Mayer E., et al. (2012) Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 10: 385-390.
13. Brown E., Xue Q., Jiang Z., Xu Y., DuPont H., (2010) Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 54: 388-396.
14. Brummond N., Locke G. III, Choung R., Chang J., Schleck C., Zinsmeister A., et al. (2015) Effects of birth cohorts on the irritable bowel syndrome support early-life risk factors. Dig Dis Sci 60: 2112-2118.
15. Camilleri M., (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367: 1626-1635.
16. Camilleri M., Klee E., Shin A., Carlson P., Li Y., Grover M., et al. (2014) Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. Am J Physiol Gastrointest Liver Physiol 306: G13-G26.
17. Camilleri M., Mayer E., Drossman D., Heath A., Dukes G., McSorley D., et al. (1999) Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13: 1149-1159.
18. Camilleri M., McKinzie S., Busciglio I., Low P., Sweetser S., Burton D., et al. (2008) Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6: 772-781.
19. Canavan C., West J., Card T., (2014) Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 40: 1023-1034.
20. Carroll I., Ringel-Kulka T., Keku T., Chang Y., Packey C., Sartor R., et al. (2011) Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 301: G799-G807.
21. Castro J., Harrington A., Hughes P., Martin C., Ge P., Shea C., et al. (2013) Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology 145: 1334-1346.
22. Chadwick V., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., et al. (2002) Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778-1783.
23. Chang L., Ameen V., Dukes G., McSorley D., Carter E., Mayer E., (2005) A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 100: 115-123.
24. Chang L., Lembo A., Sultan S., (2014) American Gastroenterological Association technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 147: 1149-1172.
25. Chang L., Sundaresh S., Elliott J., Anton P., Baldi P., Licudine A., et al. (2009) Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 21: 149-159.
26. Chang L., Tong K., Ameen V., (2010) Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol 105: 866-875.
27. Cheng J., Shah Y., Ma X., Pang X., Tanaka T., Kodama T., et al. (2010) Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335: 32-41.
28. Chey W., Camilleri M., Chang L., Rikner L., Graffner H., (2011) A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 106: 1803-1812.
29. Chey W., Lembo A., Lavins B., Shiff S., Kurtz C., Currie M., et al. (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107: 1702-1712.
30. Chitkara D., van Tilburg M., Blois-Martin N., Whitehead W., (2008) Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 103: 765-774.
31. Choung R., Locke G. III, Zinsmeister A., Schleck C., Talley N., (2009) Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 104: 1772-1779.
32. Clayton A., Montejo A., (2006) Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67 (Suppl. 6): 33-37.
33. Coates M., Mahoney C., Linden D., Sampson J., Chen J., Blaszyk H., et al. (2004) Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664.
34. Codling C., O'Mahony L., Shanahan F., Quigley E., Marchesi J., (2010) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55: 392-397.
35. Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., et al. (2010) Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 105: 1181-1188.
36. Debbia E., Maioli E., Roveta S., Marchese A., (2008) Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 20: 186-194.
37. Delvaux M., Beck A., Jacob J., Bouzamondo H., Weber F., Frexinos J., (2004) Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 20: 237-246.
38. Delvaux M., Louvel D., Mamet J., Campos-Oriola R., Frexinos J., (1998) Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 12: 849-855.
39. Di Stefano M., Tana P., Mengoli C., Miceli E., Pagani E., Corazza G., (2011) Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med 6: 403-411.
40. Didari T., Mozaffari S., Nikfar S., Abdollahi M., (2015) Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 21: 3072-3084.
41. Dossett M., Davis R., Lembo A., Yeh G., (2014) Complementary and alternative medicine use by US adults with gastrointestinal conditions: results from the 2012 National Health Interview Survey. Am J Gastroenterol 109: 1705-1711.
42. Dove L., Lembo A., Randall C., Fogel R., Andrae D., Davenport J., et al. (2013) Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 145: 329-338.
43. Drossman D., (2006) Rome III diagnostic criteria for functional gastrointestinal disorders. In: Rome III: The functional GI disorders. MacLean, VA: Degnon Associates, Inc., pp 885-897.
44. Drossman D., Chang L., Bellamy N., Gallo-Torres H., Lembo A., Mearin F., et al. (2011) Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 106: 1749-1759.
45. Drossman D., Chey W., Johanson J., Fass R., Scott C., Panas R., et al. (2009a) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29: 329-341.
46. Drossman D., Morris C., Schneck S., Hu Y., Norton N., Norton W., et al. (2009b) International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 43: 541-550.
47. DuPont H., Jiang Z., (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and Enterococci. Clin Microbiol Infect 10: 1009-1011.
48. Durbán A., Abellán J., Jiménez-Hernández N., Artacho A., Garrigues V., Ortiz V., et al. (2013) Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol 86: 581-589.
49. Durbán A., Abellán J., Jimenéz-Hernández N., Salgado P., Ponce M., Ponce J., et al. (2012) Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 4: 242-247.
50. Ek W., Reznichenko A., Ripke S., Niesler B., Zucchelli M., Rivera N., et al. (2015) Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. [published online ahead of print 23, 2014 ]. Gut 64: 1774-1782.
51. Eser A., Colombel J., Rutgeerts P., Vermeire S., Vogelsang H., Braddock M., et al. (2015) Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn's disease: a randomized placebo-controlled, double-blind, phase IIa study. Inflamm Bowel Dis 21: 2247-2253.
52. Feagan B., Macdonald J., (2012) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 10: CD000543.
53. Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., et al. (2014) Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 264: 651-660.
54. Ford A., Achkar J., Khan K., Kane S., Talley N., Marshall J., et al. (2011) Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 106: 601-616.
55. Ford A., Moayyedi P., Lacy B., Lembo A., Saito Y., Schiller L., et al.; Task Force on the Management of Functional Bowel Disorders. (2014a) American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109: S2-S26.
56. Ford A., Quigley E., Lacy B., Lembo A., Saito Y., Schiller L., et al. (2014b) Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109: 1350-1365.
57. Forest Laboratories, Inc. (2014) Linzess (linaclotide) capsules, for oral use [package insert]. St. Louis, MO: Forest Laboratories, Inc.
58. Fukudo S., Kaneko H., Akiho H., Inamori M., Endo Y., Okumura T., et al. (2015) Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol 50: 11-30.
59. Garsed K., Chernova J., Hastings M., Lam C., Marciani L., Singh G., et al. (2014) A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63: 1617-1625.
60. Gershon M., (1999) Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 13 (Suppl. 2): 15-30.
61. Gershon M., (2004) Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20 (Suppl. 7): 3-14.
62. Gershon M., Tack J., (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414.
63. Gibson P., Varney J., Malakar S., Muir J., (2015) Food components and irritable bowel syndrome. Gastroenterology 148: 1158-1174.
64. Goebel-Stengel M., Stengel A., Schmidtmann M., Voort I., Kobelt P., Monnikes H., (2014) Unclear abdominal discomfort: pivotal role of carbohydrate malabsorption. J Neurogastroenterol Motil 20: 228-235.
65. Grasberger H., Chang L., Shih W., Presson A., Sayuk G., Newberry R., et al. (2013) Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol 108: 1766-1774.
66. Guilarte M., Santos J., de Torres I, Alonso C., Vicario M., Ramos L., et al. (2007) Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56: 203-209.
67. Gulewitsch M., Enck P., Hautzinger M., Schlarb A., (2011) Irritable bowel syndrome symptoms among German students: prevalence, characteristics, and associations to somatic complaints, sleep, quality of life, and childhood abdominal pain. Eur J Gastroenterol Hepatol 23: 311-316.
68. Halland M., Almazar A., Lee R., Atkinson E., Larson J., Talley N., et al. (2014) A case-control study of childhood trauma in the development of irritable bowel syndrome. Neurogastroenterol Motil 26: 990-998.
69. Hoang M., Defina L., Willis B., Leonard D., Weiner M., Brown E., (2011) Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc 86: 1050-1055.
70. Holliday E., Attia J., Hancock S., Koloski N., McEvoy M., Peel R., et al. (2014) Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Am J Gastroenterol 109: 770-772.
71. Holzer P., (2009) Opioid receptors in the gastrointestinal tract. Regul Pept 155: 11-17.
72. Hopkins K., Mushtaq S., Richardson J., Doumith M., de Pinna E., Cheasty T., et al. (2014) In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK. Int J Antimicrob Agents 45: 431-437.
73. Hughes P., Castro J., Harrington A., Isaacs N., Moretta M., Hicks G., et al. (2014a) Increased kappa-opioid receptor expression and function during chronic visceral hypersensitivity. Gut 63: 1199-1200.
74. Hughes P., Moretta M., Lim A., Grasby D., Bird D., Brierley S., et al. (2014b) Immune derived opioidergic inhibition of viscerosensory afferents is decreased in irritable bowel syndrome patients. Brain Behav Immun 42: 191-203.
75. Hungin A., Molloy-Bland M., Claes R., Heidelbaugh J., Cayley W. Jr, Muris J., et al. (2014) Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care-a Rome Foundation working team report. Aliment Pharmacol Ther 40: 1133-1145.
76. Hungin A., Chang L., Locke G., Dennis E., Barghout V., (2005) Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 21: 1365-1375.
77. Jeffery I., O'Toole P., Ohman L., Claesson M., Deane J., Quigley E., et al. (2012) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61: 997-1006.
78. Jiang Z., DuPont H., La Rocco M., Garey K., (2010a) In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 63: 355-358.
79. Jiang Z., Ke S., DuPont H., (2010b) Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 35: 278-281.
80. Johannesson E., Simren M., Strid H., Bajor A., Sadik R., (2011) Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 106: 915-922.
81. Kang S., Choi S., Lee S., Chung W., Lee H., Chung K., et al. (2011) The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. Gut Liver 5: 472-477.
82. Karaahmet F., Basar O., Yuksel I., Coban S., Yuksel O., (2013) Letter: vitamin D supplementation and the irritable bowel syndrome. Aliment Pharmacol Ther 37: 499.
83. Khan M., Nusrat S., Khan M., Nawras A., Bielefeldt K., (2015) Low-FODMAP diet for irritable bowel syndrome: is it ready for prime time? Dig Dis Sci 60: 1169-1177.
84. Khanna R., Macdonald J., Levesque B., (2014) Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48: 505-512.
85. Klooker T., Braak B., Koopman K., Welting O., Wouters M., van der Heide S., et al. (2010) The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59: 1213-1221.
86. Knight J., Locke G. III, Zinsmeister A., Schleck C., Talley N., (2015) Family history of mental illness or alcohol abuse and the irritable bowel syndrome. J Psychosom Res 78: 237-241.
87. Koloski N., Jones M., Kalantar J., Weltman M., Zaguirre J., Talley N., (2012) The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 61: 1284-1290.
88. Ladabaum U., Boyd E., Zhao W., Mannalithara A., Sharabidze A., Singh G., et al. (2012) Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 10: 37-45.
89. Lamki L., Sullivan S., (1983) A study of gastrointestinal opiate receptors: the role of the Mu receptor on gastric emptying: concise communication. J Nucl Med 24: 689-692.
90. Larsson M., Tillisch K., Craig A., Engstrom M., Labus J., Naliboff B., et al. (2012) Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology 142: 463-472.
91. Layer P., Stanghellini V., (2014) Review article: linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 39: 371-384.
92. Lembo A., Pimentel M., Rao S., Schoenfeld P., Cash B., Weinstock L., et al. (2014) Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study. Presented at: American College of Gastroenterology (ACG) 2014 Annual Scientific Meeting, Philadelphia, PA, 17-22 October 2014.
93. Levy R., Jones K., Whitehead W., Feld S., Talley N., Corey L., (2001) Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 121: 799-804.
94. Lin S., Mooney P., Kurien M., Aziz I., Leeds J., Sanders D., (2014) Prevalence, investigational pathways and diagnostic outcomes in differing irritable bowel syndrome subtypes. Eur J Gastroenterol Hepatol 26: 1176-1180.
95. Locke G. III, Zinsmeister A., Talley N., Fett S., Melton L. III., (2000) Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 75: 907-912.
96. Longstreth G., Thompson W., Chey W., Houghton L., Mearin F., Spiller R., (2006) Functional bowel disorders. Gastroenterology 130: 1480-1491.
97. Lovell R., Ford A., (2012) Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 107: 991-1000.
98. Maccaferri S., Vitali B., Klinder A., Kolida S., Ndagijimana M., Laghi L., et al. (2010) Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 65: 2556-2565.
99. Macdougall J., Johnston J., Lavins B., Nelson L., Williams V., Carson R., et al. (2013) An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil 25: 481-486.
100. Madisch A., Holtmann G., Plein K., Hotz J., (2004) Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 19: 271-279.
101. Mangel A., Bornstein J., Hamm L., Buda J., Wang J., Irish W., et al. (2008) Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28: 239-249.
102. Mangel A., Hicks G., (2012) Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. Clin Exp Gastroenterol 5: 1-10.
103. Martínez C., Vicario M., Ramos L., Lobo B., Mosquera J., Alonso C., et al. (2012) The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol 107: 736-746.
104. Matsueda K., Harasawa S., Hongo M., Hiwatashi N., Sasaki D., (2008a) A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 77: 225-235.
105. Matsueda K., Harasawa S., Hongo M., Hiwatashi N., Sasaki D., (2008b) A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43: 1202-1211.
106. Melchior C., Gourcerol G., Déchelotte P., Leroi A., Ducrotté P., (2014) Symptomatic fructose malabsorption in irritable bowel syndrome: A prospective study. United Eur Gastroenterol J 2: 131-137.
107. Mencarelli A., Migliorati M., Barbanti M., Cipriani S., Palladino G., Distrutti E., et al. (2010) Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 80: 1700-1707.
108. Mencarelli A., Renga B., Palladino G., Claudio D., Ricci P., Distrutti E., et al. (2011) Inhibition of NF-kB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 668: 317-324.
109. Menees S., Maneerattannaporn M., Kim H., Chey W., (2012) The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107: 28-35.
110. Miller V., Hopkins L., Whorwell P., (2004) Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2: 1064-1068.
111. Miner P., DeLuca R., La Portilla M., Padila E., Koltun W., Wiltz O., et al. (2014) 1831. Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trail to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol: S541-S541.
112. Mitchell C., Drossman D., (1987) Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 92: 1282-1284.
113. Muir J., Gibson P., (2013) The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. Gastroenterol Hepatol (N Y) 9: 450-452.
114. Patheon Pharmaceuticals, Inc. (2015) Viberzi (eluxadoline) tablets, for oral use, CIV [package insert]. Cincinnati, OH: Patheon Pharmaceuticals, Inc.
115. Patcharatrakul T., Gonlachanvit S., (2011) Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome. J Clin Gastroenterol 45: 593-598.
116. Patel P., Bercik P., Morgan D., Bolino C., Pintos-Sanchez M., Moayyedi P., et al. (2015) Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which. drive bloating. Aliment Pharmacol Ther 41: 449-458.
117. Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J., et al. (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196-201.
118. Pimentel M., Chang C., Chua K., Mirocha J., DiBaise J., Rao S., et al. (2014) Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 59: 1278-1285.
119. Pimentel M., Lembo A., Chey W., Zakko S., Ringel Y., Yu J., et al.; TARGET Study Group. (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: 22-32.
120. Pimentel M., Park S., Mirocha J., Kane S., Kong Y., (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: 557-563.
121. Posserud I., Syrous A., Lindstrom L., Tack J., Abrahamsson H., Simren M., (2007) Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 133: 1113-1123.
122. ® (alosetron hydrochloride) tablets [package insert]. San Diego, CA: Prometheus Laboratories, Inc.
123. Prott G., Shim L., Hansen R., Kellow J., Malcolm A., (2010) Relationships between pelvic floor symptoms and function in irritable bowel syndrome. Neurogastroenterol Motil 22: 764-769.
124. Quigley E., Tack J., Chey W., Rao S., Fortea J., Falques M., et al. (2013) Randomised clinical trials: linaclotide phase 3 studies in IBS-C-a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 37: 49-61.
125. Rana S., Sharma S., Sinha S., Parsad K., Malik A., Singh K., (2012) Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 33: 251-256.
126. Rao A., Wong B., Camilleri M., Odunsi-Shiyanbade S., McKinzie S., Ryks M., et al. (2010) Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139: 1549-58, 1558.
127. Rao S., Lembo A., Shiff S., Lavins B., Currie M., Jia X., et al. (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107: 1714-1724.
128. Rao S., Quigley E., Shiff S., Lavins B., Kurtz C., Macdougall J., et al. (2014) Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 12: 616-623.
129. Rasmussen S., Jensen T., Henriksen S., Haastrup P., Larsen P., Sondergaard J., et al. (2015) Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol 50: 162-169.
130. Rey de, Castro N., Miller V., Carruthers H., Whorwell P., (2015) Irritable bowel syndrome: a comparison of subtypes. J Gastroenterol Hepatol 30: 279-285.
131. Ringel Y., Ringel-Kulka T., (2011) The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 45: S145-S148.
132. Ringel Y., Williams R., Kalilani L., Cook S., (2009) Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 7: 68-72.
133. Saadi M., McCallum R., (2013) Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis 4: 71-75.
134. Saito Y., Schoenfeld P., Locke G. III,. (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 97: 1910-1915.
135. Salvioli B., Pellegatta G., Malacarne M., Pace F., Malesci A., Pagani M., et al. (2015) Autonomic nervous system dysregulation in irritable bowel syndrome. Neurogastroenterol Motil.
136. Scarpellini E., Gabrielli M., Lauritano C., Lupascu A., Merra G., Cammarota G., et al. (2007) High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 25: 781-786.
137. Schiller L., Johnson D., (2008) Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. Am J Gastroenterol 103: 815-819.
138. Schmulson M., Lee O., Chang L., Naliboff B., Mayer E., (1999) Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 94: 2929-2935.
139. Schrodt C., McHugh E., Gawinowicz M., DuPont H., Brown E., (2013) Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS One 8: e68550.
140. Sethi S., Wadhwa V., LeClair J., Mikami S., Park R., Jones M., et al. (2013) In-patient discharge rates for the irritable bowel syndrome-an analysis of national trends in the United States from 1997 to 2010. Aliment Pharmacol Ther 38: 1338-1346.
141. Shah E., Kim S., Chong K., Lembo A., Pimentel M., (2012) Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 125: 381-393.
142. Shah S., Day L., Somsouk M., Sewell J., (2013) Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 38: 925-934.
143. Singh P., Agnihotri A., Pathak M., Shirazi A., Tiwari R., Sreenivas V., et al. (2012) Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. J Neurogastroenterol Motil 18: 324-331.
144. Sprake E., Grant V., Corfe B., (2012) Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centered data. BMJ Case Rep.
145. Su A., Shih W., Presson A., Chang L., (2014) Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil 26: 36-45.
146. Szarka L., Camilleri M., Burton D., Fox J., McKinzie S., Stanislav T., et al. (2007) Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 5: 1268-1275.
147. Takeda Pharmaceuticals America, Inc. (2013) Amitiza (lubiprostone) capsules [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.
148. Talley N., Phillips S., Melton L., Mulvihill C., Wiltgen C., Zinsmeister A., (1990) Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 31: 77-81.
149. Terc J., Hansen A., Alston L., Hirota S., (2014) Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur J Pharm Sci 55: 12-19.
150. Tillisch K., Mayer E., Labus J., (2011) Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 140: 91-100.
151. Tong K., Nicandro J., Shringarpure R., Chuang E., Chang L., (2013) A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 6: 344-357.
152. Tornblom H., Van O., Sadik R., Abrahamsson H., Tack J., Simren M., (2012) Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 107: 754-760.
153. Trinkley K., Nahata M., (2014) Medication management of irritable bowel syndrome. Digestion 89: 253-267.
154. Vazquez-Roque M., Camilleri M., Smyrk T., Murray J., Marietta E., O'Neill J., et al. (2013) A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 144: 903-911.
155. Vicario M., Gonzalez-Castro A., Martinez C., Lobo B., Pigrau M., Guilarte M., et al. (2014) Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut 64: 1379-1388.
156. Vivinus-Nébot M., Dainese R., Anty R., Saint-Paul M., Nano J., Gonthier N., et al. (2012) Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 107: 75-81.
157. Vivinus-Nébot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., et al. (2014) Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63: 744-752.
158. Wade P., Chen J., Jaffe B., Kassem I., Blakely R., Gershon M., (1996) Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16: 2352-2364.
159. Wade P., Palmer J., McKenney S., Kenigs V., Chevalier K., Moore B., et al. (2012) Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/ micro opioid receptor antagonist. Br J Pharmacol 167: 1111-1125.
160. Walker M., Talley N., Prabhakar M., Pennaneac'h C., Aro P., Ronkainen J., et al. (2009) Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 29: 765-773.
161. Whelan K., (2014) Editorial: The importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 109: 1563-1565.
162. Wong R., Palsson O., Turner M., Levy R., Feld A., Von K., et al. (2010) Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 105: 2228-2234.
163. Wouters M., Lambrechts D., Knapp M., Cleynen I., Whorwell P., Agreus L., et al. (2014) Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut 63: 1103-1111.
164. Xu D., Gao J., Gillilland M. III, Wu X., Song I., Kao J., et al. (2014) Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146: 484-496.
165. Yin K., Agrawal D., (2014) Vitamin D and inflammatory diseases. J Inflamm Res 7: 69-87.
166. Yu S., Rao S., (2014) Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol 7: 193-205.